The agency suggested that clinical trials in humans may be required for updated Covid shots, raising questions about whether they will be available in the fall.
Category: Placebos
-
Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report
But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who benefited said the improvement didn’t last.
-
What the Polio Vaccine Has Meant for Public Health
A lawyer working with Robert F. Kennedy Jr. has asked the F.D.A. to withdraw approval of the current shot because it hasn’t been tested against a placebo. Scientists say such a test would be unethical.
-
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
-
FDA Panel Rejects Use of MDMA for Treatment of PTSD
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
-
FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws
The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.
-
The Psychedelic Evangelist
A Johns Hopkins scientist was known for rigorous studies of psychedelics. Was he a true believer?
-
Wegovy, the Weight Loss Drug, Relieves Heart Failure Symptoms: Drugmaker’s Study
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.
-
F.D.A. Approves New Treatment for Early Alzheimer’s
The New York Times – Business:The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
-
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The New York Times – Business:The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.